Jan A Burger

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5352342/publications.pdf

Version: 2024-02-01

215 papers	24,174 citations	7069 78 h-index	7718 150 g-index
218 all docs	218 docs citations	218 times ranked	16206 citing authors

#	Article	IF	Citations
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2013, 369, 32-42.	13.9	2,019
2	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2015, 373, 2425-2437.	13.9	1,261
3	CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood, 2006, 107, 1761-1767.	0.6	1,063
4	Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cellâ€“derived factor-1. Blood, 2000, 96, 2655-2663.	0.6	648
5	Three-year follow-up of treatment-naÃ¯ve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood, 2015, 125, 2497-2506.	0.6	618
6	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood, 2012, 119, 1182-1189.	0.6	564
7	The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood, 2009, 114, 3367-3375.	0.6	504
8	The phosphoinositide 3â€²-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood, 2011, 118, 3603-3612.	0.6	489
9	Chronic Lymphocytic Leukemia B Cells Express Functional CXCR4 Chemokine Receptors That Mediate Spontaneous Migration Beneath Bone Marrow Stromal Cells. Blood, 1999, 94, 3658-3667.	0.6	443
10	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. Lancet Oncology, The, 2014, 15, 48-58.	5.1	438
11	Ibrutinib and Venetoclax for First-Line Treatment of CLL. New England Journal of Medicine, 2019, 380, 2095-2103.	13.9	388
12	Single-agent ibrutinib in treatment-naÃ¯ve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience. Blood, 2018, 131, 1910-1919.	0.6	339
13	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020, 34, 787-798.	3.3	321
14	Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncology, The, 2014, 15, 1090-1099.	5.1	315
15	Final analysis from RESONATE: Up to six years of followâ€up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. American Journal of Hematology, 2019, 94, 1353-1363.	2.0	305
16	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood, 2015, 125, 2062-2067.	0.6	303
17	Targeting B cell receptor signalling in cancer: preclinical and clinical advances. Nature Reviews Cancer, 2018, 18, 148-167.	12.8	299
18	Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nature Cell Biology, 2012, 14, 276-286.	4.6	295

#	Article	IF	Citations
19	CXCR4 is a prognostic marker in acute myelogenous leukemia. Blood, 2007, 109, 786-791.	0.6	291
20	Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. Nature Communications, 2016, 7, 11589.	5.8	285
21	Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood, 2009, 114, 4441-4450.	0.6	284
22	High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. Blood, 2009, 113, 3050-3058.	0.6	283
23	B cell receptor signaling in chronic lymphocytic leukemia. Trends in Immunology, 2013, 34, 592-601.	2.9	282
24	Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood, 2005, 106, 1824-1830.	0.6	275
25	Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL. Blood, 2019, 134, 851-859.	0.6	259
26	Functional expression of CXCR4 (CD184) on small-cell lung cancer cells mediates migration, integrin activation, and adhesion to stromal cells. Oncogene, 2003, 22, 8093-8101.	2.6	255
27	CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene, 2005, 24, 4462-4471.	2.6	249
28	The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: Insight into disease biology and new targeted therapies. Seminars in Cancer Biology, 2014, 24, 71-81.	4.3	242
29	A phase 2 study of idelalisib plus rituximab in treatment-naÃ¯ve older patients with chronic lymphocytic leukemia. Blood, 2015, 126, 2686-2694.	0.6	224
30	Distinctive features of â€œnurselikeâ€•cells that differentiate in the context of chronic lymphocytic leukemia. Blood, 2002, 99, 1030-1037.	0.6	223
31	Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinibâ€based regimens. Cancer, 2015, 121, 3612-3621.	2.0	220
32	B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood, 2009, 114, 1029-1037.	0.6	210
33	Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood, 2007, 110, 3316-3325.	0.6	203
34	10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematology,the, 2020, 7, e724-e736.	2.2	201
35	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. Haematologica, 2017, 102, 1796-1805.	1.7	200
36	Duvelisib, a novel oral dual inhibitor of PI3K-Î´,Î³, is clinically active in advanced hematologic malignancies. Blood, 2018, 131, 877-887.	0.6	199

#	Article	IF	Citations
37	The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood, 2014, 123, 1032-1039.	0.6	182
38	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab. Blood, 2019, 133, 2031-2042.	0.6	178
39	Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. Biochimica Et Biophysica Acta - Molecular Cell Research, 2016, 1863, 401-413.	1.9	175
40	Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood, 2009, 113, 4604-4613.	0.6	172
41	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood, 2019, 133, 1011-1019.	0.6	168
42	Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood, 2011, 117, 3016-3024.	0.6	164
43	CD49d Is the Strongest Flow Cytometryâ€“Based Predictor of Overall Survival in Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2014, 32, 897-904.	0.8	162
44	Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia. Blood, 2011, 118, 3489-3498.	0.6	161
45	Treatment of Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2020, 383, 460-473.	13.9	157
46	Fibroblast-like synoviocytes support B-cell pseudoemperipolesis via a stromal cellâ€“derived factor-1â€“ and CD106 (VCAM-1)â€“dependent mechanism. Journal of Clinical Investigation, 2001, 107, 305-315.	3.9	156
47	Nurture versus Nature: The Microenvironment in Chronic Lymphocytic Leukemia. Hematology American Society of Hematology Education Program, 2011, 2011, 96-103.	0.9	152
48	The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. British Journal of Haematology, 2007, 137, 288-296.	1.2	148
49	The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. Nature Communications, 2017, 8, 2185.	5.8	148
50	AT-101 induces apoptosis in CLL B cells and overcomes stromal cellâ€“mediated Mcl-1 induction and drug resistance. Blood, 2009, 113, 149-153.	0.6	140
51	Phase II Study of Lenalidomide and Rituximab As Salvage Therapy for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2013, 31, 584-591.	0.8	137
52	Chemokine Receptors and Stromal Cells in the Homing and Homeostasis of Chronic Lymphocytic Leukemia B Cells. Leukemia and Lymphoma, 2002, 43, 461-466.	0.6	135
53	Isoform-selective phosphoinositide 3â€²-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cellâ€“mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood, 2009, 113, 5549-5557.	0.6	135
54	Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765). Leukemia and Lymphoma, 2013, 54, 2385-2391.	0.6	134

#	Article	IF	Citations
55	Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL. Blood, 2014, 123, 3727-3732.	0.6	133
56	Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leukemia and Lymphoma, 2015, 56, 1643-1650.	0.6	130
57	Multivariable Model for Time to First Treatment in Patients With Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2011, 29, 4088-4095.	0.8	124
58	Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study. Clinical Cancer Research, 2020, 26, 3918-3927.	3.2	123
59	Evolution of CLL treatment â€" from chemoimmunotherapy to targeted and individualized therapy. Nature Reviews Clinical Oncology, 2018, 15, 510-527.	12.5	114
60	Secondary mutations as mediators of resistance to targeted therapy in leukemia. Blood, 2015, 125, 3236-3245.	0.6	113
61	CCL3 (MIP-1Î±) plasma levels and the risk for disease progression in chronic lymphocytic leukemia. Blood, 2011, 117, 1662-1669.	0.6	112
62	Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL. Blood, 2017, 129, 2612-2615.	0.6	111
63	Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2. Haematologica, 2018, 103, 1502-1510.	1.7	111
64	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. Cancer Cell, 2015, 27, 409-425.	7.7	109
65	Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood, 2013, 121, 1501-1509.	0.6	107
66	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood, 2015, 125, 2915-2922.	0.6	104
67	Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood, 2011, 118, 3818-3823.	0.6	103
68	Longâ€term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer, 2017, 123, 2268-2273.	2.0	103
69	Bruton's Tyrosine Kinase: From X-Linked Agammaglobulinemia Toward Targeted Therapy for B-Cell Malignancies. Journal of Clinical Oncology, 2014, 32, 1830-1839.	0.8	95
70	Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): From understanding the basics towards therapeutic targeting. Seminars in Cancer Biology, 2010, 20, 424-430.	4.3	94
71	Bruton Tyrosine Kinase Inhibitors. Cancer Journal (Sudbury, Mass), 2019, 25, 386-393.	1.0	94
72	Ibrutinib Therapy Increases T Cell Repertoire Diversity in Patients with Chronic Lymphocytic Leukemia. Journal of Immunology, 2017, 198, 1740-1747.	0.4	92

#	Article	IF	Citations
73	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemiaÂ. Blood Advances, 2022, 6, 3440-3450.	2.5	91
74	Brutonâ€™s Tyrosine Kinase (BTK) Inhibitors in Clinical Trials. Current Hematologic Malignancy Reports, 2014, 9, 44-49.	1.2	90
75	Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies. Blood Advances, 2019, 3, 1799-1807.	2.5	90
76	Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13906-13911.	3.3	86
77	Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood, 2014, 123, 4132-4135.	0.6	86
78	Bone Marrow Stromaâ€“Secreted Cytokines Protect JAK2V617F-Mutated Cells from the Effects of a JAK2 Inhibitor. Cancer Research, 2011, 71, 3831-3840.	0.4	84
79	Ibrutinib modifies the function of monocyte/macrophage population in chronic lymphocytic leukemia. Oncotarget, 2016, 7, 65968-65981.	0.8	84
80	Potential of CXCR4 antagonists for the treatment of metastatic lung cancer. Expert Review of Anticancer Therapy, 2011, 11, 621-630.	1.1	81
81	The PI3-Kinase Delta Inhibitor Idelalisib (GS-1101) Targets Integrin-Mediated Adhesion of Chronic Lymphocytic Leukemia (CLL) Cell to Endothelial and Marrow Stromal Cells. PLoS ONE, 2013, 8, e83830.	1.1	80
82	Molecular Pathways: Targeting the Microenvironment in Chronic Lymphocytic Leukemiaâ€”Focus on the B-Cell Receptor. Clinical Cancer Research, 2014, 20, 548-556.	3.2	79
83	Development of novel CXCR4-based therapeutics. Expert Opinion on Investigational Drugs, 2012, 21, 341-353.	1.9	78
84	Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib. JCI Insight, 2017, 2, e89904.	2.3	78
85	Ublituximab and umbralisib in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood, 2019, 134, 1811-1820.	0.6	75
86	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. British Journal of Haematology, 2019, 184, 558-569.	1.2	71
87	CXCR4 chemokine receptors (CD184) and Î±4Î²1 integrins mediate spontaneous migration of human CD34+ progenitors and acute myeloid leukaemia cells beneath marrow stromal cells (pseudoemperipolesis). British Journal of Haematology, 2003, 122, 579-589.	1.2	70
88	Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies. Cytokine, 2018, 109, 11-16.	1.4	70
89	Phase I study of single-agent CC-292, a highly selective Brutons tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia. Haematologica, 2016, 101, e295-e298.	1.7	67
90	Th17 and non-Th17 interleukin-17-expressing cells in chronic lymphocytic leukemia: delineation, distribution, and clinical relevance. Haematologica, 2012, 97, 599-607.	1.7	65

#	Article	IF	Citations
91	The bruton tyrosine kinase inhibitor ibrutinib (<scp>PCI</scp>â€32765) blocks hairy cell leukaemia survival, proliferation and <scp>B</scp> cell receptor signalling: a new therapeutic approach. British Journal of Haematology, 2014, 166, 177-188.	1.2	65
92	Stimulation of the B-cell receptor activates the JAK2/STAT3 signaling pathway in chronic lymphocytic leukemia cells. Blood, 2014, 123, 3797-3802.	0.6	65
93	Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia. Journal of Experimental Medicine, 2018, 215, 681-697.	4.2	65
94	Tolerability and activity of ublituximab, umbralisib, and ibrutinib in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: a phase 1 dose escalation and expansion trial. Lancet Haematology,the, 2019, 6, e100-e109.	2.2	65
95	Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK. Blood, 2017, 129, 1155-1165.	0.6	64
96	CXCR4 chemokine receptor antagonists: perspectives in SCLC. Expert Opinion on Investigational Drugs, 2009, 18, 481-490.	1.9	63
97	Outcomes of first-line treatment for chronic lymphocytic leukemia with 17p deletion. Haematologica, 2014, 99, 1350-1355.	1.7	62
98	Safety Analysis of Four Randomized ControlledÂStudies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 648-657.e15.	0.2	62
99	Five-Year Experience with Single-Agent Ibrutinib in Patients with Previously Untreated and Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia. Blood, 2016, 128, 233-233.	0.6	60
100	Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Current Opinion in Oncology, 2012, 24, 643-649.	1.1	57
101	Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Clinical Cancer Research, 2017, 23, 1149-1155.	3.2	57
102	Brutonâ€™s tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL). Expert Opinion on Investigational Drugs, 2018, 27, 31-42.	1.9	57
103	Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Advances, 2021, 5, 1876-1883.	2.5	56
104	Cell Trafficking in Chronic Lymphocytic Leukemia. Open Journal of Hematology, 2012, 3, 1.	0.4	56
105	Use of anticoagulants and antiplatelet in patients with chronic lymphocytic leukaemia treated with singleâ€agent ibrutinib. British Journal of Haematology, 2017, 178, 286-291.	1.2	55
106	The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies. Seminars in Cancer Biology, 2011, 21, 308-312.	4.3	53
107	Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia. JAMA Oncology, 2021, 7, 1213.	3.4	53
108	Influence of bone marrow stromal microenvironment on forodesine-induced responses in CLL primary cells. Blood, 2010, 116, 1083-1091.	0.6	52

#	Article	IF	Citations
109	The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2313-2324.	3.2	51
110	CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma. British Journal of Haematology, 2015, 171, 726-735.	1.2	50
111	Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia. Current Hematologic Malignancy Reports, 2012, 7, 26-33.	1.2	48
112	Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. , 2014, 144, 338-348.		47
113	Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 2154-2158.	3.2	47
114	Idelalisibâ€"targeting PI3KÎ´ in patients with B-cell malignancies. Nature Reviews Clinical Oncology, 2014, 11, 184-186.	12.5	46
115	PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL). Current Topics in Microbiology and Immunology, 2015, 393, 123-142.	0.7	46
116	Duvelisib, an oral dual PI3Kâ€Î´,Î³ inhibitor, shows clinical and pharmacodynamic activity in chronic lymphocytic leukemia and small lymphocytic lymphoma in a phase 1 study. American Journal of Hematology, 2018, 93, 1318-1326.	2.0	45
117	Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy. Blood, 2019, 134, 1951-1959.	0.6	45
118	Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib. Haematologica, 2016, 101, e254-e258.	1.7	40
119	Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide. Blood, 2018, 131, 1820-1832.	0.6	40
120	Ibrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemia. Leukemia Research, 2020, 97, 106432.	0.4	40
121	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia, 2019, 33, 287-298.	3.3	39
122	Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight, 2018, 3, .	2.3	39
123	Phosphorylated CXCR4 is associated with poor survival in adults with Bâ€acute lymphoblastic leukemia. Cancer, 2011, 117, 4689-4695.	2.0	38
124	CCL3 chemokine expression by chronic lymphocytic leukemia cells orchestrates the composition of the microenvironment in lymph node infiltrates. Leukemia and Lymphoma, 2016, 57, 563-571.	0.6	34
125	Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies. Leukemia, 2018, 32, 2388-2398.	3.3	34
126	Resistance Mutations to BTK Inhibitors Originate From the NF-ÎºB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. Frontiers in Immunology, 2021, 12, 689472.	2.2	32

#	Article	IF	Citations
127	Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study. Blood, 2013, 122, 525-525.	0.6	32
128	Three Newly Approved Drugs for Chronic Lymphocytic Leukemia: Incorporating Ibrutinib, Idelalisib, and Obinutuzumab into Clinical Practice. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 385-391.	0.2	31
129	Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic Leukemia. Journal of Immunology, 2016, 197, 2522-2531.	0.4	31
130	Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL). Blood, 2013, 122, 1630-1630.	0.6	29
131	Ofatumumab and Lenalidomide for Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia: Correlation between Responses and Immune Characteristics. Clinical Cancer Research, 2016, 22, 2359-2367.	3.2	28
132	The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naiˆve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease: New and Updated Results of 116 Patients in a Phase Ib/II Study. Blood, 2012, 120, 189-189.	0.6	28
133	Effects of pharmacological and genetic disruption of CXCR4 chemokine receptor function in Bâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 174, 425-436.	1.2	27
134	Outcomes with ibrutinib by line of therapy and postâ€ibrutinib discontinuation in patients with chronic lymphocytic leukemia: Phase 3 analysis. American Journal of Hematology, 2019, 94, 554-562.	2.0	27
135	Association of gene mutations with timeâ€toâ€first treatment in 384 treatmentâ€naive chronic lymphocytic leukaemia patients. British Journal of Haematology, 2019, 187, 307-318.	1.2	26
136	Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia. Frontiers in Oncology, 2018, 8, 369.	1.3	25
137	Myeloid-derived suppressor cell subtypes differentially influence T-cell function, T-helper subset differentiation, and clinical course in CLL. Leukemia, 2021, 35, 3163-3175.	3.3	25
138	Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia. American Journal of Hematology, 2016, 91, E478-E479.	2.0	24
139	Singleâ€agent ibrutinib versus chemoimmunotherapy regimens for treatmentâ€naÃ¯ve patients with chronic lymphocytic leukemia: A crossâ€trial comparison of phase 3 studies. American Journal of Hematology, 2018, 93, 1402-1410.	2.0	24
140	Impact of long-term ibrutinib treatment on circulating immune cells in previously untreated chronic lymphocytic leukemia. Leukemia Research, 2021, 102, 106520.	0.4	24
141	Zanubrutinib for treatmentâ€naÃ¯ve and relapsed/refractory chronic lymphocytic leukaemia: longâ€term followâ€up of the phase I/II AUâ€003 study. British Journal of Haematology, 2022, 196, 1209-1218.	1.2	24
142	The CXCR4â€“STAT3â€“IL-10 Pathway Controls the Immunoregulatory Function of Chronic Lymphocytic Leukemia and Is Modulated by Lenalidomide. Frontiers in Immunology, 2017, 8, 1773.	2.2	23
143	Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory Bâ€cell malignancies: Results of a phase I study. American Journal of Hematology, 2019, 94, E90-E93.	2.0	23
144	The Btk Inhibitor Ibrutinib (PCI-32765) in Combination with Rituximab Is Well Tolerated and Displays Profound Activity in High-Risk Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2012, 120, 187-187.	0.6	23

#	Article	IF	Citations
145	The lymphatic tissue microenvironments in chronic lymphocytic leukemia: in vitro models and the significance of CD40-CD154 interactions. Blood, 2009, 114, 2560-2561.	0.6	22
146	Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (iFCG) regimen for chronic lymphocytic leukemia (CLL) with mutated IGHV and without TP53 aberrations. Leukemia, 2021, 35, 3421-3429.	3.3	22
147	Preliminary Results From A Phase I Dose Escalation Study to Determine the Maximum Tolerated Dose of Plerixafor In Combination with Rituximab In Patients with Relapsed Chronic Lymphocytic Leukemia. Blood, 2010, 116, 2450-2450.	0.6	22
148	Update on a Phase 2 Study of Idelalisib in Combination with Rituximab in Treatment-NaÃ¯ve Patients â‰¥65 Years with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). Blood, 2014, 124, 1994-1994.	0.6	21
149	The Bruton's Tyrosine Kinase Inhibitor, PCI-32765, Is Well Tolerated and Demonstrates Promising Clinical Activity In Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL): An Update on Ongoing Phase 1 Studies. Blood, 2010, 116, 57-57.	0.6	20
150	Cross-talk between chronic lymphocytic leukemia cells and bone marrow endothelial cells: role of signal transducer and activator of transcription 3. Human Pathology, 2011, 42, 1989-2000.	1.1	19
151	The CLL Cell Microenvironment. Advances in Experimental Medicine and Biology, 2013, 792, 25-45.	0.8	19
152	Routine sequencing in <scp>CLL</scp> has prognostic implications and provides new insight into pathogenesis and targeted treatments. British Journal of Haematology, 2019, 185, 852-864.	1.2	19
153	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia, 2020, 34, 1588-1598.	3.3	18
154	Phosphoinositide 3â€²-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia. Oncotarget, 2011, 2, 737-738.	0.8	18
155	Ibrutinib: a paradigm shift in management of CLL. Expert Review of Hematology, 2014, 7, 705-717.	1.0	17
156	Characterizing the kinetics of lymphocytosis in patients with chronic lymphocytic leukemia treated with single-agent ibrutinib. Leukemia and Lymphoma, 2019, 60, 1000-1005.	0.6	17
157	A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma, 2019, 60, 3461-3469.	0.6	16
158	Ibrutinib induces durable remissions in treatment-naÃ¯ve patients with CLL and 17p deletion and/or TP53 mutations. Blood, 2021, 138, 2589-2592.	0.6	16
159	The microenvironment in hairy cell leukemia: pathways and potential therapeutic targets. Leukemia and Lymphoma, 2011, 52, 94-98.	0.6	15
160	BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma. Leukemia, 2021, 35, 2621-2634.	3.3	15
161	The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer Journal, 2021, 11, 57.	2.8	15
162	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood, 2019, 133, 2056-2068.	0.6	14

#	Article	IF	Citations
163	CXCL13 plasma levels function as a biomarker for disease activity in patients with chronic lymphocytic leukemia. Leukemia, 2021, 35, 1610-1620.	3.3	14
164	Angiopoietin-2 in CLL. Blood, 2010, 116, 508-509.	0.6	13
165	Chronic lymphocytic leukemia therapy: new targeted therapies on the way. Expert Opinion on Pharmacotherapy, 2016, 17, 1077-1089.	0.9	13
166	Continuous high-dose ivermectin appears to be safe in patients with acute myelogenous leukemia and could inform clinical repurposing for COVID-19 infection. Leukemia and Lymphoma, 2020, 61, 2536-2537.	0.6	13
167	The Great Imitator: Systemic Nocardiosis Mimicking Richter's Transformation in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2010, 28, e732-e734.	0.8	11
168	Trisomy 12 is associated with an abbreviated redistribution lymphocytosis during treatment with the <scp>BTK</scp> inhibitor ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2015, 170, 125-128.	1.2	11
169	Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results. Blood, 2020, 136, 42-43.	0.6	11
170	Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica, 2017, 102, e394-e396.	1.7	10
171	Dynamic changes of the normal B lymphocyte repertoire in CLL in response to ibrutinib or FCR chemo-immunotherapy. OncoImmunology, 2018, 7, e1417720.	2.1	10
172	Tumour debulking and reduction in predicted risk of tumour lysis syndrome with singleâ€agent ibrutinib in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2019, 186, 184-188.	1.2	10
173	Achieving complete remission in CLL patients treated with ibrutinib: clinical significance and predictive factors. Blood, 2020, 135, 510-513.	0.6	10
174	Bruton's Tyrosine Kinase Inhibitor PCI-32765 Abrogates BCR- and Nurselike Cell-Derived Activation of CLL Cells In Vitro and In Vivo.. Blood, 2010, 116, 45-45.	0.6	10
175	Pattern of Use of Anticoagulation and/or Antiplatelet Agents in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Single-Agent Ibrutinib Therapy. Blood, 2014, 124, 1990-1990.	0.6	10
176	Functional Evidence from Deuterated Water Labeling That the Bruton Tyrosine Kinase Inhibitor Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death in Patients with Chronic Lymphocytic Leukemia and small Lymphocytic Lymphoma. Blood, 2014, 124, 326-326.	0.6	10
177	B cell receptor isotypes differentially associate with cell signaling, kinetics, and outcome in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2022, 132, .	3.9	10
178	Ibrutinib provides favourable survival outcomes in patients with comorbidities versus established therapies. British Journal of Haematology, 2019, 186, 175-180.	1.2	9
179	Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL. Blood Advances, 2019, 3, 1533-1539.	2.5	9
180	Activation and expansion of T-follicular helper cells in chronic lymphocytic leukemia nurselike cell co-cultures. Leukemia, 2022, 36, 1324-1335.	3.3	9

#	Article	IF	Citations
181	BCR-Mediated Decrease of CXCR4 and CD62L in CLL â€“ Letter. Cancer Research, 2010, 70, 5194-5194.	0.4	8
182	The importance of the tissue microenvironment in hairy cell leukemia. Best Practice and Research in Clinical Haematology, 2015, 28, 208-216.	0.7	8
183	Obinutuzumab: the more the merrier?. Blood, 2016, 127, 6-8.	0.6	8
184	Consolidation treatment with lenalidomide following front-line or salvage chemoimmunotherapy in chronic lymphocytic leukemia. Haematologica, 2017, 102, e494-e496.	1.7	8
185	A phase <scp>II</scp> trial of eltrombopag for patients with chronic lymphocytic leukaemia (<scp>CLL</scp>) and thrombocytopenia. British Journal of Haematology, 2019, 185, 606-608.	1.2	8
186	Adhesion of Hairy Cells Leukemia (HCL) Cells to Stromal Cells Can Be Inhibited by Blocking VLA-4 Integrins and CXCR4 Chemokine Receptors. Blood, 2011, 118, 1760-1760.	0.6	8
187	Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leukemia and Lymphoma, 2022, 63, 1375-1386.	0.6	8
188	Ibrutinib Can Modulate the T Cell Response in Chronic Lymphocytic Leukemia By Reducing PD1/PDL1 Interactions. Blood, 2015, 126, 1737-1737.	0.6	7
189	CLL progression after one cycle of FCR: <scp>R</scp>ichter's transformation versus EBVâ€associated lymphoâ€proliferation. American Journal of Hematology, 2017, 92, 1113-1114.	2.0	6
190	TP53â€altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitorâ€based therapy: A retrospective analysis. American Journal of Hematology, 2022, 97, 1005-1012.	2.0	6
191	No cell is an island unto itself: The stromal microenvironment in chronic lymphocytic leukemia. Leukemia Research, 2007, 31, 887-888.	0.4	5
192	The addition of <scp>CD</scp>20 monoclonal antibodies to lenalidomide improves response rates and survival in relapsed/refractory patients with chronic lymphocytic leukaemia relative to lenalidomide monotherapy â€“ the <scp>MD</scp> Anderson Cancer Center experience. British Journal of Haematology, 2015, 171, 281-284.	1.2	5
193	Dynamic changes in <scp>CCL</scp>3 and <scp>CCL</scp>4 plasma concentrations in patients with chronic lymphocytic leukaemia managed with observation. British Journal of Haematology, 2018, 180, 597-600.	1.2	5
194	Survival adjusting for crossover: phase 3 study of ibrutinib vs . chlorambucil in older patients with untreated chronic lymphocytic leukemia/small lymphocytic lymphoma. Haematologica, 2018, 103, e249-e251.	1.7	5
195	Proteomic profiling based classification of CLL provides prognostication for modern therapy and identifies novel therapeutic targets. Blood Cancer Journal, 2022, 12, 43.	2.8	5
196	Imatinib mesylate-induced long-term remission in extra-medullary T-cell lymphoid blastic phase of chronic myelogenous leukemia. Leukemia and Lymphoma, 2006, 47, 2427-2430.	0.6	4
197	The times they are a-changin': prognostic markers in the new era of BCR-targeting therapies for CLL. Expert Opinion on Medical Diagnostics, 2012, 6, 49-57.	1.6	4
198	The landscape of genetic mutations in patients with chronic lymphocytic leukaemia and complex karyotype. British Journal of Haematology, 2019, 187, e1-e4.	1.2	4

#	Article	IF	Citations
199	RPPA-based proteomics recognizes distinct epigenetic signatures in chronic lymphocytic leukemia with clinical consequences. Leukemia, 2022, 36, 712-722.	3.3	4
200	Outcomes of First-Line Ibrutinib in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and High-Risk Genomic Features with up to 6.5 Years Follow-up: Integrated Analysis of Two Phase 3 Studies (RESONATE-2 and iLLUMINATE). Blood, 2020, 136, 25-26.	0.6	4
201	Sustained long-lasting responses after lenalidomide discontinuation in patients with chronic lymphocytic leukemia. Leukemia, 2018, 32, 2278-2281.	3.3	3
202	LPL deletion is associated with poorer response to ibrutinib-based treatments and overall survival in TP53-deleted chronic lymphocytic leukemia. Annals of Hematology, 2020, 99, 2343-2349.	0.8	3
203	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 130-137.	0.3	3
204	Integrating New Therapies for Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury, Mass), 2021, 27, 275-285.	1.0	3
205	The CXCR4 Score: A New Prognostic Marker in Acute Myelogenous Leukemia.. Blood, 2004, 104, 1072-1072.	0.6	3
206	Disrupting the food chain in B cell lymphomas: co-operation between CXCR4 antagonists and antibodies. Leukemia and Lymphoma, 2012, 53, 3-4.	0.6	2
207	Development of a cell-line model to mimic the pro-survival effect of nurse-like cells in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 45-57.	0.6	2
208	Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2021, 194, 61-68.	1.2	2
209	Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors. Leukemia and Lymphoma, 2022, , 1-9.	0.6	2
210	Fledgling prognostic markers in CLL. Blood, 2007, 110, 3820-3821.	0.6	1
211	HSP90, a chaperone that can make you SYK. Blood, 2017, 129, 542-544.	0.6	1
212	CLL cells are moved by the MARCKS brothers. Blood, 2021, 138, 503-504.	0.6	1
213	New pieces in the BTKi resistance puzzle. Blood, 2018, 131, 1995-1996.	0.6	0
214	Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clinical Cancer Research, 2019, 25, 2372-2374.	3.2	0
215	The Bone Marrow Microenvironment and Its Impact in Acute and Chronic B Cell Malignancies. , 2012, , 35-45.		0